세계 자간전증 진단 시장 규모는 2025-2032년 예측 기간 동안 3.67%의 CAGR로 성장할 것으로 예상됩니다. 시장 성장은 주로 자간전증의 유병률 증가와 관련 위험 요인에 대한 임산부 및 의료진의 인식이 높아짐에 따라 촉진될 것으로 예상됩니다. 또한, 주요 시장 기업들의 지속적인 제품 개발 활동은 2025-2032년 예측 기간 동안 시장 확대에 더욱 기여할 것으로 예상됩니다.
자간전증 진단의 시장 역학
전 세계적으로 자간전증의 유병률 증가로 인해 자간전증 진단 시장이 크게 성장하고 있습니다. 세계보건기구(WHO)(2024)의 데이터에 따르면, 자간전증은 전 세계 임신의 2-8%에 영향을 미칩니다. 이 임신 관련 합병증은 주로 임신 20주 이후에 발생하는 고혈압과 장기 손상의 징후가 특징이며, 많은 여성들이 직면하고 있기 때문에 조기 진단 방법에 대한 요구가 꾸준히 증가하고 있습니다.
또한, UK Obstetric Surveillance System(UKOSS)의 연구에 따르면, 중증 비만 환자의 자간전증 발병률은 9%인 반면, 비만이 아닌 대조군에서는 2%였습니다. 또한, Preeclampsia Foundation Organization(2024)이 제공한 자료에 따르면, 임신성 고혈압, 만성 고혈압, 자간전증, 자간증 등의 질환을 포함한 임신성 고혈압 증후군(HDP)은 전 세계 전체 임신의 약 5-10%에 영향을 미치고 있습니다.
자간전증은 HDP의 주요하고 가장 심각한 병태생리로, 혈압 상승과 장기, 특히 간과 신장의 손상 징후를 특징으로 하며, HDP가 계속해서 심각한 건강 위험을 초래함에 따라 전 세계적으로 자간전증 진단 기술의 채택이 증가할 것으로 예상됩니다. 모체 연령의 증가, 비만, 당뇨병, 고혈압, 다태임신 등의 요인이 자간전증의 발병 위험을 증가시키는 주요 원인으로 작용하고 있습니다. 따라서 전 세계적으로 자간전증 환자가 증가하고 있으며, 이는 자간전증 진단 시장의 성장을 견인할 것으로 예측됩니다.
임산부의 인식이 높아지는 것도 자간전증 진단 시장의 주요 성장 촉진요인입니다. 예를 들어, 2025년 1월, 1월 23일 임산부 건강 인식의 날을 기념하여 자간전증 재단은 Patients & Purpose와 공동으로 GAP-SPIRIN 캠페인을 시작했습니다. 이 증거 기반 교육 활동은 자간전증을 예방하고 임산부 건강 격차를 해소하기 위해 저용량 아스피린 사용을 장려하는 캠페인입니다.
이 캠페인은 흑인 임산부들이 직면하고 있는 특별한 문제에 대한 정보와 저용량 아스피린 예방에 대한 지침을 결합하여 의료진이 자간전증의 위험을 더 잘 관리할 수 있도록 돕습니다. 자간전증은 임신 중과 산후에 생명을 위협할 수 있는 심각한 고혈압성 질환입니다. 이 질환은 임산부 건강 위기의 핵심 문제이며, 흑인 산모에게 60%의 발병률을 보이는 등 흑인 산모에게 편향적으로 영향을 미칩니다.
시장 주요 기업들의 혁신적인 진단 테스트 개발은 시장 성장에 크게 기여하고 있으며, 2022년 5월, Mirvie는 자사의 Mirvie Preeclampsia Test가 미국 FDA의 Breakthrough Device 지정을 받았다고 발표하였습니다. 이 획기적인 검사는 증상이 나타나기 전에 여성의 자간전증 발병 위험을 개별적으로 평가할 수 있도록 설계되었습니다. 이 검사는 독자적인 미르비 RNA 플랫폼을 통해 각 임신에 고유한 생물학적 신호를 분석하여 예기치 못한 합병증 위험을 예측함으로써 보다 신속하고 개별화된 임상적 개입을 가능하게 합니다.
이러한 유망한 성장 요인에도 불구하고, 자간전증 진단 시장은 도전에 직면해 있습니다. 환자 및 의료진의 인식 부족과 자간전증 진단 검사의 정확도 한계는 예측 기간 동안 시장 성장을 저해할 수 있는 중요한 억제요인으로 작용할 수 있습니다.
세계의 자간전증 진단 시장에 대해 조사 분석했으며, 시장 규모와 예측, 최근 3년간의 제품/기술 개발, 주요 기업, 시장 기회 등의 정보를 전해드립니다.
Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of preeclampsia worldwide & associated risk factors and growing awareness among pregnant women and healthcare professionals
The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032. The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.
Preeclampsia Diagnostics Market Dynamics:
The rising prevalence of preeclampsia globally is significantly boosting the overall market for preeclampsia diagnostics. According to the data provided by the World Health Organization (2024), preeclampsia affects 2-8% of pregnancies worldwide. As more women face this pregnancy-related complication, primarily marked by high blood pressure and signs of organ damage usually occurring after the 20th week of gestation, the need for early and accurate detection methods is steadily increasing.
Additionally, the UK Obstetric Surveillance System (UKOSS) study showed an incidence of preeclampsia of 9% in severely obese patients compared to 2% of nonobese controls. Also, according to the data provided by the Preeclampsia Foundation Organization (2024), hypertensive disorders of pregnancy (HDPs), which include conditions such as gestational hypertension, chronic hypertension, preeclampsia, and eclampsia, affected approximately 5-10% of all pregnancies worldwide.
Preeclampsia is a major and most severe form of HDP, often characterized by elevated blood pressure and signs of damage to organ systems, particularly the liver and kidneys. As HDPs continue to pose significant health risks, the adoption of advanced preeclampsia diagnostic technologies is expected to boost across the globe. Factors such as increasing maternal age, obesity, diabetes, hypertension, and multiple pregnancies are key contributors to the growing risk of developing preeclampsia. Therefore, the rising cases of preeclampsia across the globe are expected to boost the growth of the preeclampsia diagnostics market.
Increasing awareness among pregnant women is another key factor driving the growth of the preeclampsia diagnostics market. For example, in January 2025, in recognition of Maternal Health Awareness Day on January 23rd, the Preeclampsia Foundation, in collaboration with Patients & Purpose, launched the "GAP-SPIRIN" campaign. This evidence-based educational initiative promotes the use of low-dose aspirin to help prevent preeclampsia and address disparities in maternal health.
The campaign combines information on the unique challenges faced by Black expectant mothers with guidance on low-dose aspirin prophylaxis, equipping healthcare providers to better manage preeclampsia risk. Preeclampsia is a severe hypertensive condition that can pose life-threatening risks during pregnancy and the postpartum period. It is a central issue in the maternal health crisis, disproportionately affecting Black mothers, who are 60% more likely to develop the condition.
The development of innovative diagnostic tests by key market players is significantly contributing to market growth. A notable example is Mirvie, which in May 2022 announced it received U.S. FDA Breakthrough Device designation for its Mirvie Preeclampsia Test. This groundbreaking test is designed to assess a woman's individualized risk of developing preeclampsia before symptoms arise. It is powered by the proprietary Mirvie RNA platform, which analyzes the unique biological signals of each pregnancy to predict the risk of unexpected complications enabling earlier and more personalized clinical intervention.
Despite these promising growth factors, the preeclampsia diagnostics market faces challenges. Limited awareness among patients and providers and limitations in the accuracy of preeclampsia diagnostic tests are significant constraints that could potentially hinder market growth during the forecast period.
Preeclampsia Diagnostics Market Segment Analysis:
Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits, and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the sample type segment of the preeclampsia diagnostics market, the blood test category held the largest revenue share in 2024. The growth of this category is attributed to the rising use of blood tests in preeclampsia diagnostics. These tests are playing a transformative role by enabling earlier, more accurate, and accessible detection of preeclampsia even before clinical symptoms manifest. Their ability to identify risk at an early stage allows for timely intervention, significantly improving maternal and fetal outcomes.
These tests provide precise risk stratification, helping clinicians predict which patients are more likely to develop severe preeclampsia. This capability supports the efficient use of hospital resources, minimizes unnecessary interventions, and enhances patient care. Moreover, blood-based diagnostics are highly scalable and easily integrated into routine prenatal care. As awareness of preeclampsia continues to grow, and as point-of-care testing becomes more accessible even in low-resource settings the demand for these tests is expected to increase.
A major advancement in this space is the development of biomarker-based blood tests, particularly those that measure levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). These biomarkers allow healthcare providers to detect preeclampsia in its early or asymptomatic stages, offering a critical tool for proactive, personalized pregnancy management.
Recent innovations in molecular diagnostics and immunoassays have led to the development of advanced blood tests for preeclampsia. For instance, companies like Thermo Fisher Scientific, PerkinElmer, and Roche Diagnostics offer blood test-based platforms for preeclampsia detection. For instance, in May 2023, the U.S. FDA approved Thermo Scientific B*R*A*H*M*S PlGF plus KRYPTOR and B*R*A*H*M*S sFlt-1 KRYPTOR novel blood-based biomarker test for the risk assessment and clinical management of preeclampsia.
Thus, all these factors are fueling the adoption of blood tests, thereby acting as a strong catalyst in the growth of the blood-based preeclampsia test, thereby driving the overall expansion of the preeclampsia diagnostics market.
North America is expected to dominate the overall Preeclampsia Diagnostics Market:
North America is projected to account for the largest share of the preeclampsia diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.
According to the recent data provided by the Centre for Disease Control and Prevention (2022), preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies in the US. Additionally, as per the same source, in the United States, the rate of preeclampsia in Black women is 60 percent higher than in White women.
Given the serious health risks it poses to both mother and baby, including preterm birth, placental abruption, and even maternal or fetal death, healthcare providers are placing increased emphasis on early screening and continuous monitoring thereby boosting the overall market of preeclampsia diagnostics across the region.
Moreover, growing product development activities among the key market players are likely to propel the revenue shares for the preeclampsia in the region. For example, In January 2024, Labcorp, a global leader in innovative and comprehensive laboratory services, announced the launch and availability of a new FDA-cleared blood test designed for the risk assessment and clinical management of severe preeclampsia, a potentially life-threatening blood pressure disorder that can occur during pregnancy and the postpartum period.
Preeclampsia Diagnostics Market Key Players:
Some of the key market players operating in the Preeclampsia Diagnostics Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.
Recent Developmental Activities in the Preeclampsia Diagnostics Market:
Key Takeaways from the Preeclampsia Diagnostics Market Report Study
Target Audience Who Can be benefited from this Preeclampsia Diagnostics Market Report Study
Frequently Asked Questions for the Preeclampsia Diagnostics Market: